Proactive Investors - Run By Investors For Investors

Adial Pharmaceuticals looks to apply its alcohol-use disorder drug to opioid-use disorder

A Phase 2b clinical trial of AD04 showed 'promising results' in treating patients with alcohol-use disorder
Bottle of prescription pills spilled onto the table
The CDC estimates that 72,000 people in the US died of drug overdoses in 2017

Adial Pharmaceuticals Inc (NASDAQ:ADIL) plans to expand the potential of its lead drug AD04, designed to treat alcohol-use disorder, to benefit patients with opioid-use disorder.

A Phase 2b clinical trial of the drug showed “promising results” in treating patients with alcohol use disorder, reducing the frequency and quantity of drinking without any serious adverse effects reported.

Shares more than doubled by Thursday’s closing bell, dipping around 8% to $3.85 in Friday pre-market trading.

READ: Anavex Life Sciences doses patients in Phase 2 ANAVEX2-73 Parkinson disease dementia study

 “We are expanding our activities around AD04 to include opioid use disorder (OUD) and believe this program has significant potential since the physiology and neuro-transmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist,” said CEO William Stilley in the company’s press statement.

The company is hopeful that AD04 can bring something to the table in an underserved market as the use of opioid and synthetic opioids, such as fentanyl, continue to contribute to overdose deaths in the US.

The Centers for Disease Control estimate that 72,000 people in the US died of drug overdoses in 2017, linking two-thirds of those deaths to opioids.

The clinical-stage biopharmaceutical company focuses on the development of treatments for addictions.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

 

View full ADIL profile View Profile

Adial Pharmaceuticals Inc Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use